National Study on Diagnosis and Treatment of Type 2 Inflammatory Skin Diseases in China A Prospective Multicenter Research Project

What this Trial Is About

Researchers are conducting a national multicenter prospective cohort study to better understand type 2 inflammatory skin diseases such as dermatitis, eczema, urticaria, pemphigoid, and prurigo nodularis. The study aims to improve diagnosis and treatment by systematically collecting data on current treatment status as well as the effectiveness and safety of various therapies in real clinical settings. This effort is led by the National Clinical Center for Skin and Immune Diseases and sponsored by Peking University First Hospital. This observational study does not involve experimental treatments but gathers information from patients receiving standard care at multiple medical units approved by the National Clinical Center for Skin and Immune Diseases. Data collection includes patient demographics, disease onset age, types of current therapies, and presence of related conditions. The study will follow patients for up to 120 months to observe treatment patterns and disease outcomes over time. Participants will provide information through questionnaires and clinical assessments at baseline and throughout the study period. Measures include the Eczema Area and Severity Index EASI, Body Surface Area affected, quality of life questionnaires, and disease activity scores related to specific skin conditions. The research team will monitor changes in therapy use, disease severity, and patient quality of life to inform future care improvements. The study started in August 2021 and will continue until December 2031.

China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project